Daneshbod Pathology Laboratory

Shīrāz, Iran

Daneshbod Pathology Laboratory

Shīrāz, Iran
SEARCH FILTERS
Time filter
Source Type

Khodakaram-Tafti A.,Shiraz University | Shirian S.,Shiraz University | Shekarforoush S.S.,Shiraz University | Fariman H.,The Iranian Veterinary Organization | Daneshbod Y.,Daneshbod Pathology Laboratory
Comparative Clinical Pathology | Year: 2011

A 3-year-old Holstein cow with a history of severe weakness, dyspnea, pale mucous membranes, increased respiratory rate associated with marked abdominal respiration, severe arrhythmia, and tachycardia was referred to a slaughterhouse by the referring veterinarian due to poor prognosis. After slaughter, a large, firm, white, multilobulated mass about 5 cm in diameter was located at the base of the heart that extended to the right atrium and obliterated partially the right atrial lumen. Microscopically, tumor cells were aligned along and around the capillaries and were discrete, cuboidal to polyhedral cells with little cytoplasm arranged in distinct packets surrounded by thin fibrous septa. The nuclei were round to oval and were placed centrally in the cells. Immunoreactivity for S100 protein was positive multifocally, mostly in the peripherally located sustentacular cells, but NSE and CrA were negative. On the basis of the clinicopathological and immunohistochemical findings, the tumor was diagnosed as aortic body chemodectoma. © 2011 Springer-Verlag London Limited.


Shahbazi M.,Pasteur Institute of Iran | Shahbazi M.,Isfahan University of Medical Sciences | Zahedifard F.,Pasteur Institute of Iran | Taheri T.,Pasteur Institute of Iran | And 9 more authors.
PLoS ONE | Year: 2015

Canine Visceral Leishmaniasis (CVL) is a major veterinary and public health problem caused by Leishmania infantum (L. infantum) in many endemic countries. It is a severe chronic disease with generalized parasite spread to the reticuloendothelial system, such as spleen, liver and bone marrow and is often fatal when left untreated. Control of VL in dogs would dramatically decrease infection pressure of L. infantum for humans, since dogs are the main domestic reservoir. In the past decade, various subunits and DNA antigens have been identified as potential vaccine candidates in experimental animal models, but none has been approved for human use so far. In this study, we vaccinated outbreed dogs with a prime-boost regimen based on recombinant L. tarentolae expressing the L. donovani A2 antigen along with cysteine proteinase genes (CPA and CPB without its unusual C-terminal extension (CPB-CTE) and evaluated its immunogenicity and protective immunity against L. infantum infectious challenge. We showed that vaccinated animals produced significantly higher levels of IgG2, but not IgG1, and also IFN-γ and TNF-α, but low IL-10 levels, before and after challenge as compared to control animals. Protection in dogs was also correlated with a strong DTH response and low parasite burden in the vaccinated group. Altogether, immunization with recombinant L. tarentolae A2-CPA-CPB-CTE was proven to be immunogenic and induced partial protection in dogs, hence representing a promising live vaccine candidate against CVL. © 2015 Shahbazi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


PubMed | Isfahan University of Medical Sciences, Laval University, Pasteur Institute of Iran, Daneshbod Pathology Laboratory and University of Tehran
Type: Controlled Clinical Trial | Journal: Veterinary parasitology | Year: 2015

Visceral leishmaniasis (VL) is a fatal disease caused by the intracellular protozoan parasite Leishmania infantum. Dogs are the primary reservoirs of this parasite, and vaccination of dogs could be an effective method to reduce its transfer to humans. In order to develop a vaccine against VL (apart from the choice of immunogenic candidate antigens), it is necessary to use an appropriate delivery system to promote a proper antigen-specific immune response. In this study, we compared two vaccine delivery systems, namely electroporation and cationic solid-lipid nanoparticle (cSLN) formulation, to administer a DNA vaccine containing the Leishmania donovani A2 antigen, and L. infantum cysteine proteinases of type I (CPA) and II (CPB) without its unusual C-terminal extension. The protective potencies of these two vaccine delivery systems were evaluated against L. infantum challenge in outbred dogs. Our results show that the administration of pcDNA-A2-CPA-CPB(-CTE)GFP vaccine as a prime-boost by either electroporation or cSLN formulation protects the dogs against L. infantum infection. Partial protection in vaccinated dogs is associated with significantly (p<0.05) higher levels of IgG2, IFN-, and TNF- and with low levels of IgG1 and IL-10 as compared to the control group. Protection was also correlated with a low parasite burden and a strong delayed-type hypersensitivity (DTH) response. This study demonstrates that both electroporation and cSLN formulation can be used as efficient vaccine delivery systems against visceral leishmaniasis.


Omidvari S.,Shiraz University of Medical Sciences | Hamedi S.H.,Shiraz University of Medical Sciences | Moaddab-Shoar L.,Shiraz University of Medical Sciences | Nasrollahi H.,Shiraz University of Medical Sciences | And 6 more authors.
Iranian Journal of Cancer Prevention | Year: 2014

Paratesticular sarcomas have happened rarely. Due to the infrequency of this malignant disease and its diverse histopathologic subtypes, no standard treatment would be available. Multiple treatments have reported in literature with different results. We have reported a 55 years old man with a 30 years history of paratesticular mass. After multiple operations, radical orchiectomy has revealed liposarcoma. The patient has been receiving 50 Gy radiation to the scrotum and inguinal area. After 18 months follow up, the patient was well and disease free. He has shown good response to surgery and radiotherapy, so we have reported the disease and its clinical course. © 2014, Cancer Research Center. All rights reserved.

Loading Daneshbod Pathology Laboratory collaborators
Loading Daneshbod Pathology Laboratory collaborators